Drugs Made In America Acquisition Corp. Ordinary Shares Total Assets

Latest as of June 2026: $146.90 Million USD

Drugs Made In America Acquisition Corp. Ordinary Shares total assets. Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) holds total assets worth $146.90 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Drugs Made In America Acquisition Corp. stock valuation for the company's overall valuation and market capitalisation.

Total Assets of Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)

Total assets of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See current stock price of Drugs Made In America Acquisition Corp. for real-time trading data and today's change.

Drugs Made In America Acquisition Corp. Ordinary Shares - Asset Composition Analysis

Drugs Made In America Acquisition Corp. Ordinary Shares Total Assets Breakdown (December 2025)

Drugs Made In America Acquisition Corp. Ordinary Shares total assets breakdown as of December 2025. Drugs Made In America Acquisition Corp. Ordinary Shares's total assets of $146.90 Million consist of 0.0% current assets and 100.0% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 0.0%
Accounts Receivable $0.00 0.0%
Inventory $0.00 0.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $0.00 0.0%
Goodwill $0.00 0.0%

Asset Composition Trend (2024–2025)

This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Drugs Made In America Acquisition Corp. working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Drugs Made In America Acquisition Corp. Ordinary Shares's current assets represent 0.0% of total assets in 2025, a decrease from 906.1% in 2024.
  • Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 245.3% in 2024.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
  • Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Total Assets

Key competitors of Drugs Made In America Acquisition Corp. Ordinary Shares based on total assets are shown below.

Company Country Total Assets
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
USA $281.56 Million
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
USA $238.54 Million
MOZAYYX Acquisition Corp.
NYSE:MZYX
USA $302.49 Million
OneIM Acquisition Corp. Class A Ordinary Shares
NASDAQ:OIM
USA $293.03 Million
SilverBox Corp V
NYSE:SBXE
USA $277.80 Million
AMR Resources Acquisition Corp Class A Ordinary Shares
NASDAQ:AMAC
USA $371.64K
M3-Brigade Acquisition V Corp. Units
NASDAQ:MBAVU
USA $308.18 Million
Renatus Tactical Acquisition Corp I Class A Ordinary Shares
NASDAQ:RTAC
USA $252.65 Million

Drugs Made In America Acquisition Corp. Ordinary Shares - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.02 0.16 0.37
Quick Ratio 0.02 0.16 0.37
Cash Ratio 0.00 0.00 0.00
Working Capital $-2.88 Million $-251.72K $-132.89

Drugs Made In America Acquisition Corp. Ordinary Shares - Advanced Valuation Insights

This section examines the relationship between Drugs Made In America Acquisition Corp. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.90
Latest Market Cap to Assets Ratio 1.09
Asset Growth Rate (YoY) 43556569.5%
Total Assets $239.92 Million
Market Capitalization $262.19 Million USD

Valuation Analysis

Above Book Valuation: The market values Drugs Made In America Acquisition Corp. Ordinary Shares's assets above their book value (1.09x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Drugs Made In America Acquisition Corp. Ordinary Shares's assets grew by 43556569.5% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)

The table below shows the annual total assets of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025.

Year Total Assets Change
2025-12-31 $239.92 Million +43556569.51%
2024-12-31 $550.82 --

About Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA USA Shell Companies
Market Cap
$264.13 Million
Market Cap Rank
#15220 Global
#3618 in USA
Share Price
$10.88
Change (1 day)
+0.00%
52-Week Range
$10.31 - $10.89
All Time High
$10.89
About

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.